US Patent Issued to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), UNIVERSITE DE PARIS, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris, Universite Libre de Bruxelles on Dec. 9 for "Antigenic peptides deriving from secretogranin V and uses thereof for the diagnosis and treatment of type 1 diabetes" (Belgian, French Inventors)

ALEXANDRIA, Va., Dec. 9 -- United States Patent no. 12,492,230, issued on Dec. 9, was assigned to INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (Paris), UNIVERSITE DE PARIS (Paris), CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (Paris), Ecole Superieure de Physique et de Chimie Industrielles de la Ville de Paris (Paris) and Universite Libre de Bruxelles (Brussels).

"Antigenic peptides deriving from secretogranin V and uses thereof for the diagnosis and treatment of type 1 diabetes" was invented by Roberto Mallone (Paris), Joelle Vinh (Paris), Yann Verdier (Paris), Decio Laks Eizirik (Brussels), Maikel Luis Colli (Brussels), Georgia Afonso (Paris) and Sergio Gonzalez-Duque (Paris).

According to the abstract* released by...